Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$1 Mln
Revenue (TTM)
$37 Mln
Net Profit (TTM)
$-111 Mln
ROE
-7.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
54.9
Industry P/E
--
EV/EBITDA
-2.2
Div. Yield
0 %
Debt to Equity
-1.8
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
3,531,710
CFO
$-559.11 Mln
EBITDA
$-512.31 Mln
Net Profit
$-716.98 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Quotient (QTNT)
| -89.5 | -46.1 | -94.9 | -99.9 | -94.5 | -82.0 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Quotient (QTNT)
| -99.6 | -50.3 | -45.2 | 55.4 | 23.5 | 2.3 | -69.8 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing... MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland. Read more
CEO & Director
Mr. Manuel O. Mendez
CEO & Director
Mr. Manuel O. Mendez
Headquarters
Eysins
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Quotient Ltd (QTNT) is $0.04 (NASDAQ) as of 03-Mar-2023 09:30 EDT. Quotient Ltd (QTNT) has given a return of -94.51% in the last 3 years.
Since, TTM earnings of Quotient Ltd (QTNT) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
The 52-week high and low of Quotient Ltd (QTNT) are Rs -- and Rs -- as of 04-Apr-2026.
Quotient Ltd (QTNT) has a market capitalisation of $ 1 Mln as on 03-Mar-2023. As per SEBI classification, it is a company.
Before investing in Quotient Ltd (QTNT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.